Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

E!10635, Eurostars, SUBERB, ATROGI AB, SU

Reference number
Coordinator ATROGI AB
Funding from Vinnova SEK 4 999 877
Project duration September 2016 - August 2019
Status Completed
Venture Eurostars

Purpose and goal

The ultimate goal is a drug for the treatment of type 2 diabetes (T2D). The purpose with the project was to develop compounds suitable as clinical candidates and to engage in a collaboration with a pharmaceutical company. A candidate drug has been nominated and large scale synthesis and formulation development for toxicological and clinical studies are ongoing. Contacts with pharmaceutical companies has been established and discussions are ongoing.

Expected effects and result

From the compounds prepared during the course of the project, we have been able to identify those that fulfill the necessary criteria of a candidate drug. The expectations at the start of the project has been surpassed as a clinical candidate already has been nominated. We also obtained results that strengthens our hypothesis on why the compounds decrease the blood glucose levels in diabetics and thus are suitable for the treatment of type 2 diabetes.

Planned approach and implementation

Compounds were iteratively designed, synthesized and analyzed in different in vitro systems. Synthetic methodologies were developed and evaluated. Several patent applications were submitted. The most interesting compounds were evaluated in more sophisticated systems, which led to the nomination of a candidate drug that is now scaled up for toxicological studies. Contacts were established with pharmaceutical companies with an interest in type 2 diabetes, as well as with several investors.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 19 March 2019

Reference number 2016-03680

Page statistics